Serum KL-6 as a marker of disease progression in SSc-ILD

C. Stock (London, United Kingdom), R. Hoyles (London, United Kingdom), C. D'Accord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), C. Campochiaro (London, United Kingdom), J. Donovan (London, United Kingdom), L. Mori (London, United Kingdom), T. Maher (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), V. Ong (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom)

Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session: CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session type: Poster Discussion
Number: 3664
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Stock (London, United Kingdom), R. Hoyles (London, United Kingdom), C. D'Accord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), C. Campochiaro (London, United Kingdom), J. Donovan (London, United Kingdom), L. Mori (London, United Kingdom), T. Maher (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), V. Ong (London, United Kingdom), C. Denton (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom). Serum KL-6 as a marker of disease progression in SSc-ILD. 3664

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
KL-6 is a useful serum biomarker for early detection of interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012


Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020


Serum markers of IPF
Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases
Year: 2004


Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010


Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021


Elevation of serum tumor markers in patients with interstitial lung disease
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011


Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Serum CC16 is a potential predictor for IPF diagnosis and prognosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis
Source: International Congress 2017 – Silicosis has not gone away
Year: 2017




Elevated serum inflammatory markers in patients with stable COPD
Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease
Year: 2009


Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D
Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease
Year: 2009

Serum neopterin and IL-6 as biomarkers in patients with COPD.
Source: International Congress 2017 – Novel molecular and genetic targets in COPD
Year: 2017


Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis
Source: Eur Respir J 2014; 43: 1530-1532
Year: 2014


KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013

Serum biomarkers in SSc-ILD: association with presence, severity and prognosis
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019


Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients
Source: Eur Respir J 2002; 20: Suppl. 38, 173s
Year: 2002

High serum levels of YKL-40 in IPF
Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology
Year: 2008


Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease
Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020
Year: 2020



The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD).
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity
Source: Eur Respir J 2005; 26: Suppl. 49, 21s
Year: 2005